Borrelia burgdorferi p31 OspA The C6 Lyme peptide ELISA is a crucial diagnostic test employed in the serological detection of Lyme disease, a tick-borne illness caused by *Borrelia burgdorferi*. This immunoassay targets antibodies against a specific synthetic peptide, known as the C6 peptide, which is derived from the VlsE surface protein of *Borrelia burgdorferi*. The development and widespread adoption of the C6 peptide ELISA have significantly advanced the accuracy and efficiency of diagnosing Lyme disease, offering a reliable method for detecting both IgG and IgM antibodies.
The C6 peptide is a conserved region of the VlsE protein, a highly immunogenic component expressed by *Borrelia burgdorferi* during infection作者：GP Wormser·2013·被引用次数：189—For the diagnosis ofLymedisease, the 2-tier serologic testing protocol forLymedisease has a number of shortcomings including low sensitivity in early .... Unlike other surface proteins that can vary, the C6 peptide remains relatively consistent across different *Borrelia* species, making it an effective target for diagnostic antibodies. When an individual is infected with Lyme disease, their immune system produces antibodies against various *Borrelia* antigens, including those that recognize the C6 peptide. The C6 Lyme peptide ELISA is designed to detect these specific antibodies in a patient's serum.
The C6 peptide ELISA utilizes the principles of enzyme-linked immunosorbent assay to quantify the presence and level of antibodies against the C6 peptide. In this assay, the C6 peptide is immobilized onto a solid surface, typically a microplate.作者：GP Wormser·2013·被引用次数：189—The C6 ELISA as a single-step serodiagnostic test providedincreased sensitivity in early Lyme diseasewith comparable sensitivity in later manifestations of ... A patient's serum sample is then added to the wells.作者：ND van Burgel·2011·被引用次数：37—With the optimal cut-off of 1.1, the sensitivity of theC6-peptide ELISAfor LNB patients in CSF was 95%, and the specificity was. 83% in the ... If antibodies specific to the C6 peptide are present in the serum, they will bind to the immobilized peptide作者：VG Pomelova·2015·被引用次数：23—Single-tier testing with the C6 peptide ELISA kitcompared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis. 2013; 75(1): 9–15. doi .... After washing away unbound components, a secondary antibody conjugated to an enzyme is added. This enzyme-linked antibody binds to the patient's antibodies that are already attached to the C6 peptide. Finally, a substrate is added, which the enzyme converts into a detectable signal, usually a color change. The intensity of the color change is proportional to the amount of C6-specific antibodies present in the serum, allowing for a quantitative assessment and helping to diagnose Lyme disease.Immunetics introduces a newB. burgdorferi (Lyme) ELISA kitbased on the C6 peptide of the VlsE protein, offering a quantum leap forward in accuracy.
The C6 Lyme peptide ELISA offers several advantages over older diagnostic methodsVlsE C6 peptide and IgG ELISA antibody analysis.... It is known for its high sensitivity and specificity, meaning it can accurately detect most cases of Lyme disease while minimizing false positive results. Research has shown that the C6 peptide ELISA can be used as a first-line screening test or as a confirmatory test in a two-tiered diagnostic approach.
One significant advantage is its ability to detect antibodies even in early stages of Lyme disease, contributing to increased sensitivity in early Lyme disease diagnosis2023年12月13日—Analytical accuracy was evaluated in comparison to aC6 Lyme ELISA™ reference method (Oxford Immunotec) with retrospectively identified serum .... Furthermore, antibodies generated from Lyme vaccination do not typically react with the C6 peptide, distinguishing between natural infection and vaccination-induced immunity. This is particularly important as the C6 peptide is derived from a naturally occurring protein, and antibodies to it indicate a natural infection.Immunetics introduces a newB. burgdorferi (Lyme) ELISA kitbased on the C6 peptide of the VlsE protein, offering a quantum leap forward in accuracy.
The C6 peptide ELISA has also demonstrated utility in diagnosing Lyme disease in patients who have previously received the OspA vaccine, a vaccine that targeted a different *Borrelia* antigen.2023年12月13日—Analytical accuracy was evaluated in comparison to aC6 Lyme ELISA™ reference method (Oxford Immunotec) with retrospectively identified serum ... Additionally, studies are exploring its potential role in diagnosing infections caused by other *Borrelia* species, such as *Borrelia miyamotoi*, suggesting a broader application in tick-borne illness diagnostics.Lyme Disease C6 Ab, Total
The performance evaluation of the C6 Lyme ELISA kit has been a subject of numerous studies, often comparing its results to standard two-step algorithms.Clinical performance and analytical accuracy of a C6 ... While the C6 ELISA can provide increased sensitivity as a single-step serodiagnostic test, especially in early Lyme disease, its role in a two-tiered approach is also well-established. In a traditional two-tiered strategy, an initial screening ELISA is followed by a more specific confirmatory test, such as Western blot or a second, more refined ELISA.作者：PJ Molloy·2018·被引用次数：50—The purpose of this study was to evaluate whether the FDA-approvedC6 peptideenzyme-linked immunosorbent assay (ELISA) currently used to diagnoseLymedisease ... The C6 Lyme ELISA can serve effectively as either the initial screening or the confirmatory step, depending on the specific protocol and its performance characteristics in different populations and stages of infection. Some research suggests that when the C6 peptide EIA is used as the second-tier test, it should be regarded as supplemental rather than solely confirmatory.
While the C6 Lyme peptide ELISA is a powerful diagnostic tool, it is essential to interpret its results in the context of a patient's clinical symptoms and exposure history. Like all diagnostic tests, it is not infallible and can have limitations. Ongoing research continues to refine these assays, exploring their effectiveness in different clinical scenarios, such as diagnosing neuroborreliosis or evaluating infections in cerebrospinal fluid (CSF). The development of kits and the ongoing performance evaluation of C6 Lyme ELISA kits aim to establish new standards in Lyme disease diagnostics, offering improved accuracy and clinical utility.
Join the newsletter to receive news, updates, new products and freebies in your inbox.